Skip to Content

Generic Kynmobi Availability

Last updated on June 8, 2021.

Kynmobi is a brand name of apomorphine, approved by the FDA in the following formulation(s):

KYNMOBI (apomorphine hydrochloride - film;sublingual)

Has a generic version of Kynmobi been approved?

No. There is currently no therapeutically equivalent version of Kynmobi available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Kynmobi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Patent 10,420,763

    Patent expiration dates:

    • June 11, 2030
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
      ✓ 
      Drug product
  • Patent 10,449,146

    Patent expiration dates:

    • April 19, 2036
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
  • Sublingual and buccal film compositions
    Patent 10,821,074
    Issued: November 3, 2020
    Assignee(s): AQUESTIVE THERAPEUTICS, INC.

    The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.

    Patent expiration dates:

    • August 7, 2029
      ✓ 
      Drug product
  • Patent 10,888,499

    Patent expiration dates:

    • February 14, 2022
      ✓ 
      Drug product
  • Patent 10,959,943

    Patent expiration dates:

    • April 19, 2036
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
  • Sublingual films
    Patent 8,414,922
    Issued: April 9, 2013
    Assignee(s): Cynapsus Therapeutics, Inc. ARx, LLC

    The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

    Patent expiration dates:

    • December 16, 2031
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
      ✓ 
      Drug product
  • Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
    Patent 8,603,514
    Issued: December 10, 2013
    Assignee(s): MonoSol RX, LLC

    The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

    Patent expiration dates:

    • April 3, 2024
      ✓ 
      Drug product
  • Film compositions for delivery of actives
    Patent 8,663,687
    Issued: March 4, 2014
    Assignee(s): MonoSol Rx, LLC

    The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films contain at least one active agent, which may be administered to a user topically, transmucosally, vaginally, ocularly, aurally, nasally, transdermally or orally.

    Patent expiration dates:

    • February 2, 2023
      ✓ 
      Drug product
  • Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
    Patent 8,765,167
    Issued: July 1, 2014
    Assignee(s): MonoSol Rx, LLC

    The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.

    Patent expiration dates:

    • February 20, 2024
      ✓ 
      Drug product
  • Sublingual films
    Patent 8,846,074
    Issued: September 30, 2014
    Assignee(s): Cynapsus Therapeutics, Inc. ARx, LLC

    The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

    Patent expiration dates:

    • December 16, 2031
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
      ✓ 
      Drug product
  • Sublingual apomorphine
    Patent 9,044,475
    Issued: June 2, 2015
    Assignee(s): Cynapsus Therapeutics, Inc.

    The invention features sublingual formulations of apomorphine that is a mucoadhesive polymer film or a strip having a first portion including an acid addition salt of apomorphine and a second portion including a pH neutralizing agent, and methods of treating Parkinson's disease, sexual dysfunction, and depressive disorders by administering sublingually the film or strip.

    Patent expiration dates:

    • June 11, 2030
      ✓ 
      Drug product
  • Sublingual films
    Patent 9,283,219
    Issued: March 15, 2016
    Assignee(s): Cynapsus Therapeutics, Inc.

    The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.

    Patent expiration dates:

    • June 11, 2030
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
      ✓ 
      Drug product
  • Sublingual apomorphine
    Patent 9,326,981
    Issued: May 3, 2016
    Assignee(s): Cynapsus Therapeutics, Inc.

    The invention features methods involving the use of sublingual film formulations of apomorphine for treating Parkinson's disease. The methods involve providing the sublingual film formulation and administering the sublingual film formulation sublingually in the mouth of a subject by contacting sublingual mucosal tissue with the film.

    Patent expiration dates:

    • June 11, 2030
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
  • Sublingual apomorphine
    Patent 9,669,019
    Issued: June 6, 2017
    Assignee(s): Sunovion Pharmaceuticals Inc.

    Disclosed are sublingual formulations of apomorphine in unit dosage form formulated for sublingual administration, where the unit dosage form is a mucoadhesive film containing a pH neutralizing agent and apomorphine particles containing an acid addition salt of apomorphine, and where the mucoadhesive film is formed by the steps of: (i) combining a film-forming mucoadhesive polymer, apomorphine particles comprising an acid addition salt of apomorphine, and a solvent to form a mixture; and (ii) pouring the mixture onto a surface and evaporating some of the solvent to form a first film comprising the apomorphine particles, where the steps further include contacting or impregnating the first film or mixture with a pH neutralizing agent to produce the mucoadhesive film containing the apomorphine particles and the pH neutralizing agent.

    Patent expiration dates:

    • June 11, 2030
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
      ✓ 
      Drug product
  • Sublingual apomorphine
    Patent 9,669,021
    Issued: June 6, 2017
    Assignee(s): Sunovion Pharmaceuticals Inc.

    Disclosed are methods of treating Parkinson's disease by (i) providing a pharmaceutical composition in unit dosage form that is a film having a first portion including apomorphine particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent, where the film contains the acid addition salt of apomorphine in an amount effective to treat Parkinson's disease, and (ii) administering the film by placing the film sublingually in the mouth of the subject and contacting sublingual mucosal tissue with the film.

    Patent expiration dates:

    • June 11, 2030
      ✓ 
      Patent use: TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
  • Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
    Patent 9,855,221
    Issued: January 2, 2018
    Assignee(s): MonoSol Rx, LLC

    The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.

    Patent expiration dates:

    • February 14, 2022
      ✓ 
      Drug product
  • Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
    Patent 9,931,305
    Issued: April 3, 2018
    Assignee(s): MonoSol Rx, LLC

    The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

    Patent expiration dates:

    • February 14, 2022
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • May 21, 2023 - NEW PRODUCT

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.